Bolt Biotherapeutics Inc.

NASDAQ: BOLT · Real-Time Price · USD
5.25
-0.19 (-3.49%)
At close: Aug 15, 2025, 3:01 PM

Bolt Biotherapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
1.22M n/a 1.14M 1.27M 5.27M 2.09M 2.53M 1.43M 1.83M 1.41M 2.11M 1.39M 813K 508K 752K n/a n/a
Cost of Revenue
n/a n/a n/a 15.43M 458K 497K 462K 1.19M 1.19M 1.17M 18.97M 18.92M 1.53M 905K 19.34M 900K 802K
Gross Profit
1.22M n/a 1.14M -14.16M 4.82M 1.59M 2.07M 244K 640K 244K -16.86M -17.53M -715K -397K -18.59M -900K -802K
Operating Income
-12.12M -16.92M -16.44M -22.6M -17.09M -19.77M -18.18M -19.83M -18.41M -21.04M -22.35M -23.06M -23.88M -27.07M -23.53M -23.76M -18.43M
Interest Income
1.05M 980K 1.27M 1.4M 1.61M 1.86M 1.93M 1.77M 1.44M 1.04M 587K 395K 198K n/a 131K 176K 56K
Pretax Income
-11.04M -15.94M -15.18M -21.2M -10.81M -17.9M -16.26M -18.06M -16.98M -20M -21.76M -22.66M -23.68M -27.16M -23.39M -23.59M -24.45M
Net Income
-11.04M -15.94M -15.18M -21.2M -10.81M -17.9M -16.26M -18.06M -15.54M -18.95M -21.76M -22.27M -23.48M -27.16M -23.39M -23.59M -24.45M
Selling & General & Admin
3.83M 3.95M 3.8M 4.87M 5.84M 5.53M 5.76M 5.62M 5.62M 5.61M 5.49M 5.53M 6.3M 5.1M 4.94M 4.05M 4.3M
Research & Development
9.51M 11.72M 13.79M 15.43M 16.07M 15.82M 14.95M 15.64M 14.63M 16.84M 18.97M 18.92M 18.39M 22.48M 19.34M 19.71M 14.13M
Other Expenses
n/a 1.25M n/a 3.56M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -6.08M
Operating Expenses
13.34M 16.92M 17.58M 19.85M 21.91M 21.36M 20.71M 21.27M 20.24M 22.45M 24.46M 24.45M 24.69M 27.58M 24.28M 23.76M 18.43M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 82K n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
13.34M 16.92M 17.58M 23.87M 22.37M 21.86M 20.71M 21.27M 20.24M 22.45M 24.46M 24.45M 24.69M 27.58M 24.28M 23.76M 18.43M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a -1.44M -1.04M n/a -395K -198K n/a n/a n/a n/a
Shares Outstanding (Basic)
38.34M 38.29M 38.25M 38.13M 38.07M 37.94M 37.87M 37.75M 37.68M 37.55M 37.45M 37.29M 37.13M 37.27M 37.21M 36.6M 34.22M
Shares Outstanding (Diluted)
38.34M 38.29M 38.25M 38.13M 38.07M 37.94M 37.87M 37.75M 37.68M 37.55M 37.45M 37.29M 37.13M 37.27M 37.21M 36.6M 34.22M
EPS (Basic)
-0.29 -0.42 -0.4 -0.56 -0.28 -0.47 -0.43 -0.48 -0.41 -0.5 -0.58 -0.6 -0.63 -0.73 -0.63 -0.64 -0.71
EPS (Diluted)
-0.29 -0.42 -0.4 -0.56 -0.28 -0.47 -0.43 -0.48 -0.41 -0.5 -0.58 -0.6 -0.63 -0.73 -0.63 -0.64 -0.71
EBITDA
-11.72M -15.51M -16M -18.57M -16.63M -19.3M -17.72M -19.37M -17.95M -20.58M -21.91M -22.65M -23.52M -26.71M -23.22M -23.5M -18.15M
EBIT
-12.12M -15.94M -16.44M -19.03M -17.09M -19.77M -18.18M -19.83M -18.41M -21.04M -22.35M -23.06M -23.88M -27.07M -23.53M -23.76M -18.43M
Depreciation & Amortization
399K 426K 440K 457K 458K 497K 462K 1.19M 1.19M 1.17M 439K 1.07M 1.53M 905K 1.06M 900K 802K